Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review
Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids. Despite its notable efficacy, bortezomib has side effects like peripheral neuropathy (PNP) with reported incidence of grade ≥3 PNP between 2%–23% Schlafer et al., 2017. Carfilzomib (CFZ) has high selectivity and minimal off-target adverse effects including lower rates of PNP. CFZ is already approved for treatment of relapsed and refractory multiple myeloma (RRMM) as single agent as well as in combination with lenalid omide and/or dexamethasone.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Adeela Mushtaq, Vikas Kapoor, Azka Latif, Ahmad Iftikhar, Umar Zahid, Ali McBride, Ivo Abraham, Irbaz Bin Riaz, Faiz Anwer Source Type: research
More News: Brain | Cancer & Oncology | Dexamethasone | Hematology | Myeloma | Neurology | Peripheral Neuropathy | Toxicology | Velcade